Rocket Pharmaceuticals (RCKT) Asset Writedowns and Impairment (2017 - 2020)
Rocket Pharmaceuticals' (RCKT) quarterly Asset Writedowns and Impairment came in at -$1000.0 in Q2 2020, down 101.59% quarter-over-quarter from $63000.0 in Q1 2020.
Rocket Pharmaceuticals (RCKT) Asset Writedowns and Impairment (2017 - 2020) Analysis & Trends
Rocket Pharmaceuticals has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting -$1000.0 for Q2 2020.
- Asset Writedowns and Impairment for Q2 2020 came in at -$1000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was -$1000.0 (down 101.61% YoY), and the FY2025 annual result was $262000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment came in at -$1000.0 for Q2 2020 at Rocket Pharmaceuticals, down from $63000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $63000.0 in Q1 2020 to a low of -$1000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Rocket Pharmaceuticals | 292.11 Mn | 292.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -1,000.00 |
| Jun 30, 2020 | -1,000.00 |
| Mar 31, 2020 | 63,000.00 |
| Mar 31, 2020 | 63,000.00 |
| Dec 31, 2017 | 14,000.00 |
| Dec 31, 2017 | 14,000.00 |